Study of the Reproducibility of the French Version of the Modified SMAFRS Scale

NCT ID: NCT07321990

Last Updated: 2026-01-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-18

Study Completion Date

2026-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to evaluate the test-retest reliability of the French version of the mSMAFRS in adult patients with SMA. The main question\[s\] is to answer if:

* ICC is a good estimate of test-retest reliability?
* mSMAFRS-F correlate with other outcome measures?

Participants will simply answer a french version of the SMA-FRS questionnaire during their routine follow-up visit then again fifteen days later.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The modified SMAFRS is a patient-reported outcome measure (PROM) designed to assess the level of independence in ten activities of daily living (ADLs) within one's own environment for individuals with SMA. Activities include eating, dressing, bathing, toileting, grooming, turning in bed/adjusting bedclothes, transfers, walking, climbing stairs, and respiratory status. Each item is scored from 0 (fully dependent) to 5 (fully independent) by the patient or caregiver, maximum score of 40. The mSMAFRS has been used in several therapeutic and 9/21 2025-A00536-43\_PROTOCOLE\_V1.2\_20250707\_mSMAFRS-F observational studies. Feasibility, test-retest reliability, construct \& content validity has been demonstrated for the English version. However currently no French version exists. Therefore, each clinician or health professional translates the items themselves during consultation with patients. This has consequences for inter-rater reliability as translations are likely to differ from one clinician to another and for intra-rater reliability as translations may differ at each visit. Therefore, successive evaluations are compromised. It is essential that an official French version exists for both clinical and research use. The added benefit of the mSMAFRS to other functional scales (e.g., MFM) is its specificity in SMA and its simplicity to perform as it is patient-reported and not observer-rated. It is useful and relevant for both ambulant and non-ambulant individuals and it includes a respiratory item which is lacking in the other functional scales.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SMA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treated patients

Questionnaire and Physical Exam

Intervention Type OTHER

Patients will answer the french mSMA-FRS during their introduction to treatment or treatment follow-up visit, then again, fifteen days after this visit.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaire and Physical Exam

Patients will answer the french mSMA-FRS during their introduction to treatment or treatment follow-up visit, then again, fifteen days after this visit.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SMA-FRS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Genetically confirmed SMA
* Able to comply with all protocol requirements (no significant cognitive impairment)
* French-speaking
* Affiliated or beneficiary of a social security scheme

Exclusion Criteria

* Persons subject to a legal protection measure
* Subjects unable to complete the French version of the questionnaire mSMAFRS-Fbecause of lack of French fluency
* Subjects unable to complete the French version of the questionnaire mSMAFRS-Fbecause of cognitive impairment
* Inability to comply with protocol requirements
* Any medical and social conditions that could interfere with the study under theappreciation of the medical coordinator
Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut de Myologie, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Association institut de Myologie

Paris, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Simone BIRNBAUM, PhD

Role: CONTACT

+330142165879

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Simone BIRNBAUM, PhD

Role: primary

+33 1 42 16 58 79

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

mSMAFRS-F

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Patient Self-managed BCI-FES
NCT03257982 COMPLETED NA